Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000200533 | SCV000250878 | likely pathogenic | not provided | 2013-04-14 | criteria provided, single submitter | clinical testing | p.Lys232Asn (AAG>AAC): c.696 G>C in exon 4 of the TGFBR1 gene (NM_004612.2) The Lys232Asn variant in the TGFBR1 gene has not been reported as a disease-causing mutation or as a benign polymorphism to our knowledge. Lys232Asn results in a semi-conservative amino acid substitution of a positively charged Lysine with a neutral, polar Asparagine at a position that is conserved across species. In silico analysis predicts Lys232Asn is probably damaging to the protein structure/function. Mutations in this codon (Lys232Glu) and in nearby residues (Glu218Lys, Phe234Leu) have been reported in association with Loeys-Dietz syndrome (LDS), further supporting the functional importance of this region of the protein. Furthermore, the Lys232Asn variant was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. In summary, while Lys232Asn is a good candidate for a disease-causing mutation, with the clinical and molecular information available at this time we cannot unequivocally determine the clinical significance of this variant. This variant was found in TAAD |